Amgen-2026 JP Morgan Healthcare Conference Presentation (01.12.26 0900AM).pdf

1、ROBERT A.BRADWAY,Chairman and Chief Executive Officer44THANNUAL J.P.MORGAN HEALTHCARE CONFERENCEJanuary 12,2026Provided January 12,2026,as part of an oral presentation and is qualified by such,contains forward-looking statements,actual results may vary materially;Amgen disclaims any duty to update.2

2、This presentation contains forward-looking statements that are based on the current expectations and beliefs of Amgen.All statements,other than statements of historical fact,are statements that could bedeemed forward-looking statements,including any statements on the outcome,benefits and synergies o

3、f collaborations,or potential collaborations,with any other company(including BeOne Medicines,Ltd.or Kyowa Kirin Co.,Ltd.),the performance of Otezla(apremilast),our acquisitions ChemoCentryx,Inc.or Horizon Therapeutics plc(including the prospective performance and outlook of Horizons business,perfor

4、mance and opportunities,and any potential strategic benefits,synergies or opportunities expected as a result of such acquisition),as well as estimates of revenues,operating margins,capitalexpenditures,cash,other financial metrics,expected legal,arbitration,political,regulatory or clinical results or

5、 practices,customer and prescriber patterns or practices,reimbursement activities and outcomes,effects of pandemics or other widespread health problems on our business,outcomes,progress,and other such estimates and results.Forward-looking statements involve significant risks and uncertainties,includ

6、ing those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen,including our most recent annual report on Form 10-K and any subsequentperiodic reports on Form 10-Q and current reports on Form 8-K.Unless otherwise noted,Amgen is providing this info